PUBLISHER: The Business Research Company | PRODUCT CODE: 1945276
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945276
Hematocrit test devices are medical instruments utilized to measure the percentage of red blood cells (RBCs) in a person's total blood volume. These devices serve various purposes, including monitoring chronic conditions, preoperative assessments, detecting blood doping, screening blood donors, managing emergencies, and conducting research and clinical trials.
The primary types of hematocrit test devices include hematocrit test meters, hematocrit test analyzers, and reagents and consumables. A hematocrit (HCT) test meter is a point-of-care device employed to measure the percentage of red blood cells in whole blood. It finds applications in conditions such as anemia, polycythemia vera, congenital heart diseases, among others, and is utilized by various end-users, including hospitals and ambulatory surgical centers, clinics, diagnostic and pathology labs, among others.
Tariffs have influenced the hematocrit test devices market by increasing costs for imported electronic components, sensors, reagents, and precision manufacturing equipment. These impacts are most visible in asia-pacific and north america, where global sourcing of diagnostic components is common. Higher costs have affected pricing for meters, analyzers, and consumables used by hospitals and diagnostic labs. However, tariffs are also encouraging local manufacturing, regional sourcing of consumables, and investments in domestic diagnostic production capabilities, supporting long-term supply chain stability.
The hematocrit test devices market research report is one of a series of new reports from The Business Research Company that provides hematocrit test devices market statistics, including hematocrit test devices industry global market size, regional shares, competitors with a hematocrit test devices market share, detailed hematocrit test devices market segments, market trends and opportunities, and any further data you may need to thrive in the hematocrit test devices industry. This hematocrit test devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hematocrit test devices market size has grown strongly in recent years. It will grow from $4.91 billion in 2025 to $5.22 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing prevalence of anemia and blood disorders, growth in hospital and laboratory diagnostic testing, rising demand for blood donor screening, expansion of emergency and trauma care services, growing awareness of hematocrit monitoring in clinical practice.
The hematocrit test devices market size is expected to see strong growth in the next few years. It will grow to $6.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising demand for point-of-care diagnostics, increasing burden of chronic and lifestyle-related diseases, expansion of decentralized healthcare and home-based testing, growing investments in diagnostic infrastructure, increasing focus on early disease detection and preventive healthcare. Major trends in the forecast period include rising adoption of point-of-care hematocrit testing devices, growing demand for rapid and accurate blood parameter assessment, increasing use of portable and handheld hematocrit meters, expansion of hematocrit testing in emergency and critical care settings, rising focus on routine screening and chronic disease monitoring.
The increasing instances of blood disorders are anticipated to drive the expansion of the hematocrit test devices market in the coming years. Blood disorders encompass conditions affecting the various components of human blood, such as red blood cells, white blood cells, platelets, and plasma. These disorders are becoming more prevalent due to a combination of factors including genetic factors, environmental pollution, and changes in lifestyle. Hematocrit test devices play a vital role in measuring the volume percentage of red blood cells in whole blood, offering essential insights into the patient's hematological well-being. For example, a report published by the American Cancer Society in January 2024 projects approximately 62,770 new cases of leukemia in the United States for 2024, leading to an estimated 23,670 deaths. Among these cases, around 20,800 new instances of acute myeloid leukemia (AML) are expected, predominantly affecting adults, with approximately 11,220 deaths attributed to AML, primarily occurring in adult patients. Thus, the rising occurrences of blood disorders are stimulating the growth of the hematocrit test devices market.
Major companies in the hematocrit test device market are focusing on advanced technologies, including user-friendly platforms tailored for medium-volume laboratories. A user-friendly platform is a system designed with intuitive features that enable fast operation with minimal training. For example, in March 2024, Mindray, a China-based health technology company, launched the BC-700 Series-a compact, integrated hematology analyzer for small to medium-sized labs that combines CBC and ESR testing in a single device. It delivers results in just 1.5 minutes, improving workflow efficiency. The system uses SF Cube 3D analysis technology for precise cell differentiation and incorporates the PLT-H parameter for enhanced platelet counting. By combining CBC and ESR testing in one unit, it reduces equipment and consumable costs. Available in both open vial and autoloader versions, the BC-700 Series provides reliable, automated, space-efficient testing with strong correlation to conventional methods, ensuring safety, accuracy, and repeatability.
In June 2023, Mars Incorporated, a US-based packaged food products manufacturer, acquired Heska Corporation for $1.3 billion. With this acquisition, Heska now operates under Mars Petcare's Science & Diagnostics division, expanding its reach in diagnostics and technology. The integration facilitates accelerated research and development efforts while enhancing global access to pet healthcare solutions. Heska Corporation specializes in manufacturing hematocrit test devices.
Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton Dickinson and Company, Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMerieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory LP, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.
North America was the largest region in the hematocrit test devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hematocrit test devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The hematocrit test devices market consists of sales of hematocrit centrifuges, test strips, capillary transfer tubes, and adapter kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hematocrit Test Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hematocrit test devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hematocrit test devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hematocrit test devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.